CliffBio

Currax Pharmaceuticals

Patent cliffs & loss of exclusivity

Small Molecules, Specialty, Generics

Company

LinkedIn URLhttps://www.linkedin.com/company/currax-pharmaceuticals-llc/
Official Websitehttp://curraxpharma.com

3 upcoming patent cliffs

DrugIngredientTypeCliff
  1. TREXIMETNAPROXEN SODIUM; SUMATRIPTAN SUCCINATESmall mol.Apr 2026
  2. TREXIMETNAPROXEN SODIUM; SUMATRIPTAN SUCCINATESmall mol.Apr 2026
  3. SILENORDOXEPIN HYDROCHLORIDESmall mol.Sep 2030
  4. SILENORDOXEPIN HYDROCHLORIDESmall mol.Sep 2030
  5. ONZETRA XSAILSUMATRIPTAN SUCCINATESmall mol.Oct 2034

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Currax Pharmaceuticals — patent cliffs & loss of exclusivity | CliffBio